Moreover, we observed that RhoF was an independent risk factor in AML patients who underwent chemotherapy alone, but not in patients who also underwent allo-HSCT, suggesting that the unfavorable effect of RhoF overexpression might be overcome by allo-HSCT. Here, RHOF is linked to acute myeloid leukemia.